Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020
December 02 2020 - 4:05PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, will host a virtual
Investor Day on Wednesday, Dec. 9, 2020, from 11:00 - 1:00 p.m.
EST. The Company plans to showcase its unique immune-dermatology
product development platform and robust pipeline of novel
drug candidates targeting multiple dermatologic indications.
Presentations will be given by Arcutis’ Senior Leadership Team in
addition to Zoe Diana Draelos, M.D., consulting professor of
dermatology, Duke University School of Medicine, Durham, N.C., and
an investigator, Dermatology Consulting Services, High Point, N.C.
A link to register for the event is available
HERE. A live audio webcast and archived replay of the presentation
will be available in the Investor Relations section of the Arcutis
website.
About Arcutis
- Bioscience, applied to the skin.Arcutis
Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology. The company is
leveraging recent advances in immunology and inflammation to
develop differentiated therapies against biologically validated
targets to solve persistent treatment challenges in serious
diseases of the skin. Arcutis’ robust pipeline includes four novel
drug candidates currently in development for a range of
inflammatory dermatological conditions. The company’s lead product
candidate, topical roflumilast, has the potential to revitalize the
standard of care for plaque psoriasis, atopic dermatitis, scalp
psoriasis, and seborrheic dermatitis. For more information, visit
www.arcutis.com or follow the company on LinkedIn and Twitter.
Investor
Contact:Heather Rowe
ArmstrongVice President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024